Stockscreener 앱 받기
6.21
0.16%
-0.010
시간 외 거래:
6.21
Aligos Therapeutics Inc 주식(ALGS)의 최신 뉴스
Aligos Hepatitis B Trial Completion: What Phase 1 Liver Data Mean for ALGS Investors - TipRanks
Aligos Therapeutics Company Profile & Introduction - Moomoo
Aligos Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits
Why (ALGS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Industry Analysts Just Upgraded Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts By 68% - Moomoo
Aligos Therapeutics (ALGS) Slips 1.55% to $6.67 as Biotech Stock Holds Above Key SupportSector Leader Stocks - vinanet.vn
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - Investing News Network
Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China - TradingView
Aligos begins phase 1 trial of hepatitis B treatment in China - Investing.com South Africa
Aligos Begins Testing a Chronic Hepatitis B Candidate in China - Stock Titan
Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts - simplywall.st
H.C. Wainwright reiterates Aligos stock rating on HBV progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates Aligos stock rating on HBV progress - Investing.com
Lake Street Keeps Their Buy Rating on Aligos Therapeutics (ALGS) - The Globe and Mail
Aligos Therapeutics Inc (NASDAQ:ALGS) - intelligentinvestor.com.au
ALGS Q2 2026 Earnings: Narrowed Loss Beats Estimates by 87% as Stock Advances 1.45Healthcare Earnings Report - Vinanet
Cantor Fitzgerald Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Aligos earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Form 8K Aligos Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Aligos Therapeutics Inc For: 6 August - Investing.com India
Aligos Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aligos Therapeutics Reports $1.5 Million Q2 Net Loss and Pipeline Progress | ALGS Stock News - Quiver Quantitative
Aligos Therapeutics 2Q 2026: Revenue $—, Net income $(1.50)M, EPS $(0.14) — 10-Q Summary - TradingView
ALGS: $27.8M licensing revenue drove a smaller Q2 loss; cash runway into Q4 2026, funding needed - TradingView
Aligos Therapeutics (Nasdaq: ALGS) logs Q2 loss but lands $27.8M HBV license revenue - Stock Titan
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
ALGS: Pipeline advances and licensing deals strengthen financials and outlook for HBV therapies - TradingView
ALIGOS THERAPEUTICS Q2 NET INCOME USD -1.504 MILLION - Moomoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Yahoo Finance
ALGS Q2'26 Earnings: EPS estimate is (1.09) USD - TradingView
Aligos Therapeutics, Inc. expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Rises 0.87% to $4.64, Holds Above SupportKey Reversal Day - dars.gov.et
Earnings Preview: ALGS to Report Financial Results Pre-market on August 06 - moomoo.com
Aligos Therapeutics Inc expected to post a loss of $1.07 a shareEarnings Preview - TradingView
Aligos Therapeutics to report results before markets open Aug. 6 - Stock Titan
Aligos Therapeutics Inc (ALGS) Cash Flow - TradingKey
Aligos Therapeutics Inc (ALGS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALGS|Aligos Therapeutics Inc|Price:7.600|Chg%:+2.010 - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.075|Chg%:-0.005 - TradingKey
Aligos Therapeutics Inc (ALGS) Income Statement - TradingKey
Aligos Therapeutics Inc (ALGS) Balance Sheet - TradingKey
Aligos Therapeutics Inc (ALGS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aligos Therapeutics Inc (ALGS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aligos Therapeutics Inc (ALGS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALGS|Aligos Therapeutics Inc|Price:4.195|Chg%:+0.115 - TradingKey
Avoiding Lag: Real-Time Signals in (ALGS) Movement - Stock Traders Daily
ALGS Q2'26 Earnings: revenue estimate is 24.68M USD - TradingView
Aligos Therapeutics (ALGS) Holds Steady Near Support Amid Cautious TradingBlock Trade Flow - dars.gov.et
H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Aligos stock rating on trial enrollment - Investing.com
0.86%
0.31%
자본화:
|
볼륨(24시간):